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Abstract
Purpose Patient ﬂow between primary care physicians
and gastroenterologists in the continuum of gastroesopha-
geal reﬂux disease (GERD) care is poorly understood.
Using administrative claims data from a large US health
plan linked with data abstracted from medical records, we
examined: health care resource utilization for GERD sub-
jects treated by primary care physicians (PCPs) and gast-
roenterologists (GEs), determinants of GERD subject
transfer between these physician types, and reasons for
GERD therapy change.
Results Within a sample of 169,884 patients, 211,043
PCP-based episodes of care and 40,304 GE-based episodes
of care were developed. In unadjusted comparisons, GE
episodes were characterized by more endoscopic proce-
dures, on average (50.5/100 episodes), compared with PCP
episodes (6.3/100, P\0.001). Multivariate analysis
showed that patients with esophagitis had 57.3% higher
odds (P\0.01) of transfer from PCP to GE compared with
patients without esophagitis; patients with esophageal
stricture had 98.6% higher odds (P\0.01) of PCP-GE
transfer. Patients with endoscopy during a ﬁrst GE episode
had 32.2% higher odds of transfer to a PCP (P\0.01).
The principal reasons for change in GERD therapy were no
change or worsening of symptoms (51.7% of PCP charts;
9.5% of GE charts) and lack of response to therapy (51.7%
of PCP charts, 26.2% of GE charts).
Conclusion Resource utilization varies greatly based on
the physician’s specialty. We infer that timely transfer of
GERD patients to gastroenterologists when empiric treat-
ment is insufﬁcient may lead to more efﬁcient clinical
management.
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Introduction
Gastroesophageal reﬂux disease (GERD) is a common
chronic condition associated with signiﬁcant morbidity,
resource consumption, and cost. An estimated 44% of the
US adult population has symptoms of heartburn at least
once per month [1], and approximately 14% of Americans
have gastroesophageal symptoms weekly, and 7% have
symptoms daily [1–3]. The annual total (direct and indi-
rect) cost associated with management of GERD is esti-
mated at more than US $14 billion in the USA, 60% of
which is spent on medication [4].
Treatment for GERD is aimed at managing symptoms
and preventing complications. According to American
College of Gastroenterology (ACG) guidelines, the initial
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acid suppression therapy should be used for patients who
have typical GERD symptoms without atypical manifes-
tations, warning signs, or symptoms suggestive of com-
plicated disease [1, 5]. Patients who respond positively to
treatment are presumed to have GERD. Further diagnostic
testing is recommended for patients who do not respond to
treatment, have symptoms (e.g., dysphagia, odynophagia,
bleeding, anemia, weight loss) suggestive of complications
or other conditions, or experience symptoms of sufﬁcient
duration to put them at risk for developing Barrett’s
esophagus [6]. Endoscopy, although it lacks sensitivity for
identifying pathologic reﬂux, is the gold standard to assess
esophageal complications of GERD [7]. While these rec-
ommendations and others exist in the literature, acceptance
at the provider level and their use in clinical practice vary
greatly [8]; this variability has signiﬁcant impact on the
cost of care.
Most of the data that provide insight into the ways that
physicians approach GERD patients come from physician
surveys. Patients with GERD symptoms frequently present
to their primary care physicians (PCPs) initially [9, 10]. A
commonly cited treatment strategy among PCPs is empiric
therapy, often using a ‘‘step-up’’ approach beginning with
antacids or H2-receptor antagonists (H2RAs) and pro-
gressing to proton pump inhibitors (PPIs) for patients who
fail to respond to therapy or who have esophagitis [11],
although results from some surveys show that PCPs may
also employ a ‘‘step-down’’ approach, beginning with PPIs
[8, 12]. PCPs often refer patients with inferred or diag-
nosed GERD to gastroenterologists or other specialists for
diagnostic endoscopy [11, 13], when symptoms are severe
or persistent [11, 13], or when patients are unresponsive to
therapy [8]. Gastroenterologists (GEs) tend to use a more
resource-intensive management approach to GERD, per-
forming diagnostic procedures before commencing a
treatment regimen, particularly for patients whose symp-
toms are moderate or severe [14, 15]. In addition, gast-
roenterologists are uniformly likely to use a step-down
therapy regimen [12, 14].
To our knowledge, there has not been a national,
administrative claims-based examination of GERD treat-
ment strategies, and the ways in which those treatment
strategies differ between PCPs and GEs. Unsuccessful
management of GERD symptoms has important implica-
tions for health care resource consumption, particularly if
GERD symptoms become chronic. The objectives of this
study were to: quantify the variation in health care resource
utilization, including pharmacologic therapy, between
PCPs and GEs treating subjects with GERD; identify the
determinants of transfers of GERD subjects between PCPs
and GEs; and ascertain the reasons for changes in GERD
therapy regimens.
Methods
The data for this study came from two sources: retro-
spective medical and pharmacy claims and enrollment
information from a large US health plan; and information
abstracted from 200 patient medical charts. The health plan
provides national coverage, with the greatest concentration
of plan members in the Midwest and South US census
regions. The health plan comprises primarily discounted
fee-for-service independent practice associations. The
administrative claims data were de-identiﬁed and compli-
ant with the provisions of the Health Insurance Portability
and Accountability Act of 1996. Medical chart data came
from records of a subset of subjects represented in the
claims-based data set who received care both from PCPs
and GEs for GERD or GERD symptoms over the study
period. The claims-based data for medical chart abstraction
candidates were re-identiﬁed upon approval from a privacy
board. Health care resource utilization was measured with
administrative claims. Reasons for transfers of GERD
subjects between PCPs and GEs, GERD therapies includ-
ing over-the-counter (OTC) medications, and reasons for
GERD therapy changes, which cannot be determined from
the claims data, were measured from variables developed
from the medical chart abstractions.
Claims Data-Based Study Sample
Subjects with claims-based evidence of GERD during the
period May 1, 2001 through November 30, 2005 were
included in the study population. The criteria for evidence
of GERD were either: (1) C2 medical claims with a pri-
mary or secondary International Classiﬁcation of Diseases,
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnosis
code for reﬂux esophagitis (530.11), esophageal reﬂux
(530.81) or heartburn (787.1); or (2) C1 medical claim with
a primary or secondary ICD-9-CM 530.11, 530.81 or 787.1
and either (a) C1 pharmacy claim for a PPI (esomeprazole,
lansoprazole, omeprazole, pantoprazole, rabeprazole), an
H2RA (cimetidine, famotidine, nizatidine, or ranitidine) or
‘‘other’’ GERD agent (bethanechol, metoclopramide,
sucralfate) or (b) C1 medical claim with a primary or
secondary ICD-9-CM code for esophageal stricture (530.3)
Barrett’s esophagus (530.85), esophageal ulcer (530.29)o r
esophagitis (530.19). The date of the ﬁrst relevant phar-
macy or medical claim was deﬁned as the index date.
Subjects in the study population also met the following
criteria: continuous enrollment in a commercial health plan
with medical and pharmacy beneﬁts for 6 months before
and at least 1 year after the index date; no medical claims
with diagnoses indicating esophageal problems that could
cast doubt on a GERD diagnosis, e.g., esophageal burns,
toxic effects of caustic or corrosive agents, effects of
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1; and no medical claims with a physician spe-
cialty code of GE for a 3-month period preceding the index
date to ensure that subjects were not under the ongoing care
of a GE at the beginning of their post-index periods.
GERD-Related Episodes
Subject-level episodes of GERD-related care were con-
structed from subjects’ index dates through the end of their
post-index date periods with Episode Treatment Groups
TM
(ETG) software developed by Symmetry Health Data
Systems
. ETGs use diagnosis codes, procedure codes, and
National Drug Codes (NDCs) to formulate clinically
homogenous episodes of care by disease condition. The
predeﬁned ETG episode categories within which GERD-
related care was identiﬁed were: infections of the stomach
and esophagus, with comorbidity; infections of the stomach
and esophagus, without comorbidity; inﬂammation of the
esophagus, with surgery; and inﬂammation of the esopha-
gus, without surgery. Episodes begin with medical claims
from clinician-provided services associated with the eval-
uation, management or treatment (e.g., physician ofﬁce
visit, surgery) of a condition [16] and end when there is an
absence of condition-related care for a minimum period of
time; for certain chronic conditions, including those used
for this study, this period of quiescence is 180 days. Sub-
jects could have multiple episodes.
Measures
Subject demographic variables included age, gender, geo-
graphic region, ‘‘new-onset’’ GERD (no medical claims
with GERD-related ICD-9-CM codes and no pharmacy
claims for GERD therapies used to identify the study
population, and no medical claims with a specialty code for
GE for any condition, during 6-month pre-index date per-
iod). Health status variables, measured during the 6-month
pre-index date period, were GERD severity and comorbid
conditions. GERD severity was a categorical variable with
three values—high, medium, and low—and was measured
with a diagnosis-based algorithm that factored in compli-
cations of GERD, comorbidities associated with GERD,
and other conditions that increase the difﬁculty of GERD
management.
2 Comorbid conditions were measured with
Clinical Classiﬁcation Software managed by the Agency
for Healthcare Research and Quality [17].
GERD-related health care utilization variables were
measured between the beginning and end of each GERD
episode. GERD-related utilization was deﬁned with the
ICD-9-CM codes used to identify the study sample, plus
ICD-9-CM codes for esophageal dyskinesia (530.5), 787.2
(dysphagia), 786.50 and 786.59 (chest pain) in the ﬁrst or
second position on the medical claim; these additional
diagnosis codes were selected based on examination of all
claims for all GERD-related ETG-based episodes for 45
subjects, and the input of a GE experienced in GERD
treatment. GERD-related utilization variables were counts
of: ofﬁce visits [Current Procedural Terminology (CPT)
codes 99201–99205, 99211–99215, 99241–99245]; endo-
scopic procedures (CPT 43200–43272, 0008T); esophageal
repair and manipulation procedures (CPT 43280–43289,
43300–43425, 43450–43460, 43499, e.g., esophagogastric
fundoplasty, esophagoplasty, esophagostomy, dilation of
esophagus); additional diagnostic procedures (e.g., esoph-
ageal motility study, Bernstein test: CPT 91010–91040);
and GERD therapy (PPI, H2RA, other GERD agent) ﬁlls.
In addition, episodes with at least one medical claim with a
diagnosis for esophageal ulcer, esophagitis, esophageal
stricture or Barrett’s esophagus in the ﬁrst or second
position on claim were identiﬁed.
All episodes were categorized as PCP, GE, or ‘‘other.’’
Attribution of episodes to physicians can be based on dif-
ferent criteria. If episode construction and attribution is
used to compare costs across physicians (i.e., physician
proﬁling), cost may be the assignment criterion. For
example, an episode may be attributed to the physician
with the highest proportion of episode-level costs, or to one
or more physicians associated with a minimum proportion
of episode-level costs [18, 19]. Episodes may also be
attributed to speciﬁc providers based on number of physi-
cian visits or other measures of utilization [19]. The utili-
zation measures counted toward physician attribution will
vary depending on the objective of the assignment, e.g.,
evaluation and management visits may be used to identify
the provider who is primarily responsible for patient care
[19]. For this study, episode attribution was intended to
identify the physician specialty principally responsible for
the management of the subject’s GERD during that epi-
sode. Therefore, utilization measures were used in order to
avoid potential misattribution based on relative cost dif-
ferences between PCPs and GEs. Episodes were catego-
rized as PCP if at least 55% of GERD-related utilization,
including ofﬁce visits, procedures, and GERD medication
ﬁlls, was associated with a PCP physician specialty code
(general practitioner, family practitioner or internal medi-
cine). Episodes were classiﬁed as GE if at least 55% of
GERD-related utilization was associated with a GE spe-
cialty code. All remaining episodes were classiﬁed as
‘‘other;’’ these episodes were characterized by specialty
codes associated with ear, nose, and throat (ENT), emer-
gency medicine, general surgery, and facilities. The 55%
1 ICD-9-CM codes are available from the corresponding author upon
request.
2 See footnote 1.
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123threshold allowed for a clear majority of care between
PCPs and GEs while assigning as many episodes to PCPs
and GEs as possible.
Medical Chart Abstraction
Medical charts for 100 subjects were abstracted. The
medical chart abstraction was designed to look speciﬁcally
at the subset of subjects who began GERD-related care
with a PCP—consistent with the way patients commonly
present with GERD symptoms based on the literature—and
were transferred from PCPs to GEs and then back to PCPs.
Criteria for subject selection were: at least two episodes;
ﬁrst episode was a PCP episode; evidence of services
provided by a GE during a PCP episode or a GE episode
subsequent to ﬁrst PCP episode; a PCP episode following
the GE episode (for subjects with a GE episode after the
ﬁrst PCP episode). Thus, based on the claims, all subjects
received GERD-related care from both PCPs and GEs in
the order PCP-GE-PCP. The last criterion was availability
of both PCP and GE charts for abstraction. Two charts, one
PCP and one GE, were abstracted for each of the 100
subjects. Information was abstracted from the medical
charts for the dates between subjects’ ﬁrst and last
observed episodes, and included: reasons that subjects were
transferred from the PCP to the GE; reasons for GERD
therapy regimen change; GERD-related symptoms; and the
circumstances of subjects’ return to PCPs after receiving
care from GEs.
Analysis
Claims- and survey-based variables were analyzed
descriptively. GERD-related utilization within episodes
was compared between PCP and GE episodes. T-test and
chi-square test were used to identify signiﬁcant differences
in unadjusted means and proportions, respectively.
Logistic regressions were estimated to identify the
determinants of subject transfer from PCP to GE, and for
transfer from GE to PCP. To model PCP-to-GE transfer,
observations for subjects with at least two episodes and a
ﬁrst PCP episode were included in the analysis. The binary,
discrete, dependent variable measured whether the subject
had at least one GE episode after the ﬁrst PCP episode
(=1). To model the GE-to-PCP transfer, observations for
subjects with multiple episodes and a ﬁrst GE episode were
analyzed. The binary, discrete, dependent variable for this
model indicated whether the subject had at least one PCP
episode after the ﬁrst GE episode (=1). Independent vari-
ables included new-onset GERD subject indicator, age,
gender, GERD severity, selected comorbid conditions, use
of a PPI, H2RA, or other GERD agent during the ﬁrst
episode, indicators of esophagitis, esophageal stricture,
esophageal ulcer, and Barrett’s esophagus during the ﬁrst
episode, and an indicator for an endoscopic procedure
during the ﬁrst episode (GE-to-PCP regression only).
Regression results are presented as odds ratios (OR) with
95% conﬁdence intervals (CI).
Results
Subject Characteristics
A total of 335,786 subjects were identiﬁed based on the
claims-based selection criteria. Of those subjects, 270,325
(80.5%) had at least one episode assigned to one of the four
predetermined GERD-related care categories. A total of
425,404 episodes were identiﬁed, for an average of 1.6
episodes per subject. Fifty-four percent (N = 227,719) of
the episodes were PCP, 46,241 (11%) were GE, and
150,444 (35%) were other. The sample of subjects included
in the analysis was limited to those with a ﬁrst episode
associated with a PCP or GE, yielding 169,884 subjects
with 251,347 episodes among them: 211,043 PCP episodes
(84.0%) and 40,304 GE episodes (16.0%).
Table 1 provides demographic and pre-index date health
status characteristics by ﬁrst-episode group. Of clinical
relevance, subjects whose ﬁrst episode was GE were sig-
niﬁcantly more likely to be classiﬁed with medium or high
GERD severity (26.23% compared with 16.81% of subjects
with a ﬁrst PCP episode, P\0.001) and other gastroin-
testinal disorders (12.40% compared with 7.14% of sub-
jects with a ﬁrst PCP episode, P\0.001). Subjects with a
ﬁrst GE episode also were signiﬁcantly more likely
(P\0.001) to have a diagnosis of esophageal ulcer (6.54%
compared with 0.63% for subjects with a ﬁrst PCP epi-
sode), esophagitis (15.34% compared with 3.19%),
esophageal stricture (5.81% compared with 0.59%), and
Barrett’s esophagus (2.07% compared with 0.20%) during
their ﬁrst episodes.
Health Care Resource Utilization
The distributions of GERD therapy strategies for all PCP
episodes and GE episodes are shown in Fig. 1. The ther-
apies represented in the PCP and GE episode categories
were based on pharmacy claims associated with PCP and
GE specialty codes, respectively (i.e., GERD therapies
prescribed by PCPs in PCP episodes and by GEs in GE
episodes).
3 Some episodes, 13.7% of PCP episodes and
3 The vast majority of GERD therapy prescriptions in PCP episodes
were associated with PCPs: 98.3% of PPI pharmacy claims, 96.8% of
H2RA claims, and 85.0% of other GERD therapy claims. Similarly,
95.9% of PPI claims, 80.4% of H2RA claims, and 86.6% of other
GERD therapy claims in GE episodes were associated with GEs.
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pharmacy claims for GERD therapies. PPIs were the sole
and predominant therapy in both types of episodes (70.0%
of PCP episodes, 67.0% of GE episodes, P\0.001). PCPs
were more likely to prescribe only H2RAs (9.3% of PCP
episodes) compared with GEs (2.9% of GE episodes,
P\0.001).
In general, GE episodes included higher levels of
unadjusted mean GERD-related utilization rates than did
PCP episodes, as shown in Table 2. GE episodes had sig-
niﬁcantly (P\0.001) higher rates per 100 of GERD-
related physician ofﬁce visits (119.9 per 100 episodes
versus 76.9 per 100 PCP episodes), endoscopic procedures
(50.5/100 versus 6.3/100 PCP episodes), repair and
manipulation procedures (3.0/100 versus 0.3/100 PCP
episodes), and additional diagnostic procedures (3.2/100
versus 0.3/100 PCP episodes). Not surprisingly, PCP epi-
sodes were characterized by signiﬁcantly higher rates of
ofﬁce visits to PCPs, while GE episodes had higher rates of
GE-speciﬁc ofﬁce visits.
Determinants of Transfers and Changes in GERD
Therapy
Logistic regression results are provided in Table 3.
Esophagitis and esophageal stricture were associated with a
Table 1 Subject characteristics
by ﬁrst episode
PCP primary care provider,
GE gastroenterologist
a These conditions were
selected based on prevalence
and clinical relevance
b Evidence is deﬁned as C1
medical claim with diagnosis
for the designated condition in
the ﬁrst or second position
First episode, PCP
(N = 142,394)
First episode, GE
(N = 27,490)
P-value
N % N %
Gender
Male 66,527 46.72 12,542 45.62 0.001
Female 75,867 53.28 14,948 54.38
Pre-index GERD severity
Low 118,447 83.18 20,280 73.77 \0.001
Medium 23,344 16.39 6,946 25.27
High 603 0.42 264 0.96
Baseline comorbid conditions
a
Respiratory infections 33,543 23.56 7,039 25.61 \0.001
Hypertension 30,154 21.18 5,149 18.73 \0.001
Disorders of lipid metabolism 29,027 20.38 5,920 21.54 \0.001
Diseases of the heart 24,715 17.36 5,182 18.85 \0.001
Upper respiratory disease 17,541 12.32 4,248 15.45 \0.001
Other lower respiratory disease 16,498 11.59 3,624 13.18 \0.001
Other gastrointestinal disorders 10,169 7.14 3,410 12.40 \0.001
Evidence of complications during ﬁrst episode
b
Ulcer 904 0.63 1,798 6.54 \0.001
Esophagitis 4,541 3.19 4,216 15.34 \0.001
Esophageal stricture 838 0.59 1,598 5.81 \0.001
Barrett’s esophagus 278 0.20 568 2.07 \0.001
Fig. 1 GERD therapies in PCP
and GE episodes. PCP primary
care physician, GE
gastroenterologist, GERD
gastroesophageal reﬂux disease,
PPI proton pump inhibitor,
H2RA H2-receptor antagonist
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12357.3% (CI: 1.299–1.905) and 98.6% (CI: 1.380–2.857)
higher odds of transfer to a GE, respectively. Subjects with
upper respiratory disease were 1.282 times (CI: 1.142–
1.439) more likely to be transferred. New-onset GERD
subjects were 37.8% more likely (CI: 1.263–1.503) to be
transferred from a PCP to a GE than were subjects with
GERD-related care before their index dates. Use of PPIs
(OR: 0.503, CI: 0.448–0.552) and H2RAs (OR: 0.665, CI:
0.585–0.756) during the ﬁrst PCP episode were associated
with signiﬁcantly lower odds of transfer to a GE. Age was
inversely associated with the odds of transfer from a PCP
to GE; that is, younger patients were more likely to be
transferred, although the effect was very small.
Many of the results from the GE-to-PCP model com-
plemented the results of the PCP-to-GE model. GERD
complications were associated with lower odds of transfer
to PCP: signiﬁcant GERD complications were esophageal
ulcer (OR: 0.633, CI: 0.520–0.771) and Barrett’s esopha-
gus (OR: 0.375, CI: 0.235–0.599). Higher levels of GERD
severity were associated with lower odds of transfer from
GE to PCP (OR: 0.849, CI: 0.757–0.951). Endoscopic
procedures administered during a ﬁrst GE episode were
associated with 32.2% higher odds (CI: 1.174–1.490) of
transfer to a PCP. New-onset GERD subjects were 15.3%
more likely (CI: 1.039–1.279) to be transferred from a GE
to a PCP. All classes of GERD therapy were associated
Table 2 GERD-related health
care utilization (unadjusted)
PCP primary care physician,
GE gastroenterologist, SD
standard deviation
a All variables are rates per 100
episodes
GERD-related utilization rate
a PCP episodes
(N = 211,043)
GE episodes
(N = 40,304)
P-value
Mean (SD) Mean (SD)
Any physician ofﬁce visit 76.9 (94.2) 119.9 (102.1) \0.001
PCP ofﬁce visit 75.2 (89.0) 4.3 (22.4) \0.001
GE ofﬁce visit 1.2 (11.8) 113.9 (87.9) \0.001
Endoscopic procedures 6.3 (33.2) 50.5 (85.7) \0.001
Repair/manipulation procedures 0.3 (7.5) 3.0 (22.5) \0.001
Diagnostic procedures 0.3 (7.5) 3.2 (24.8) \0.001
Table 3 Determinants of
transfer: logistic regression
results
PCP primary care physician,
GE gastroenterologist, PPI
proton pump inhibitor, H2RA
H2-receptor antagonist
* 0.01 B P\0.05;
** P \0.01
PCP-to-GE model GE-to-PCP model
Odds ratio 95% CI Odds ratio 95% CI
New-onset GERD 1.378 (1.263–1.503)** 1.153 (1.039–1.279)**
Age 0.996 (0.993–0.999)* 1.012 (1.008–1.016)**
Male 0.764 (0.703–0.831)** 0.932 (0.846–1.027)
Pre-index date health status
GERD severity 0.942 (0.840–1.056) 0.849 (0.757–0.951)**
Disorders of lipid metabolism 1.062 (0.953–1.183) 1.010 (0.894–1.140)
Hypertension 0.851 (0.760–0.953)** 1.189 (1.048–1.348)**
Respiratory infections 0.962 (0.872–1.062) 1.017 (0.907–1.140)
Disease of the heart 1.052 (0.938–1.181) 0.920 (0.808–1.046)
Other lower respiratory disease 1.040 (0.911–1.188) 1.008 (0.871–1.166)
Other gastrointestinal disorders 1.118 (0.949–1.316) 1.131 (0.969–1.322)
Lower gastrointestinal disorders 1.196 (0.929–1.540) 1.169 (0.922–1.483)
Other upper respiratory disease 1.282 (1.142–1.439)** 0.950 (0.831–1.085)
Any PPI use in ﬁrst episode 0.503 (0.458–0.552)** 0.595 (0.531–0.667)**
Any H2RA use in ﬁrst episode 0.665 (0.585–0.756)** 0.820 (0.691–0.974)*
Any other GERD therapy use in ﬁrst episode 1.034 (0.842–1.271) 0.817 (0.679–0.983)*
Esophagitis in ﬁrst episode 1.573 (1.299–1.905)** 0.969 (0.836–1.124)
Esophageal ulcer in ﬁrst episode 1.101 (0.734–1.651) 0.633 (0.520–0.771)**
Esophageal stricture in ﬁrst episode 1.986 (1.380–2.857)** 0.947 (0.774–1.159)
Barrett’s esophagus in ﬁrst episode 1.369 (0.627–2.990) 0.375 (0.235–0.599)**
Endoscopy during ﬁrst GE episode – – 1.322 (1.174–1.490)**
Observations (N) 62,704 11,318
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CI = 0.531–0.667; H2RA: OR = 0.820, CI = 0.691–
0.974; other: OR = 0.817, CI = 0.679–0.983). In this
model, age was positively associated with the likelihood of
transfer from GE to PCP; with each increasing year of age,
the odds of a GE-to-PCP transfer increased by 1.2%.
Additional analysis was undertaken to determine whe-
ther the higher prevalence rates of esophageal ulcer,
esophagitis, esophageal stricture, and Barrett’s esophagus
in ﬁrst GE episodes were biased due to GEs’ diagnostic
approach; that is, were higher proportions of GE episodes
characterized with esophageal ulcer, esophagitis, esopha-
geal stricture, and Barrett’s esophagus because GEs were
more likely to perform endoscopies and, consequently,
diagnose these conditions? To evaluate the possibility of
such bias, the prevalence of each of these conditions was
compared between ﬁrst PCP and GE episodes that included
endoscopic procedures. The results of these comparisons
are as follows: 10.8% of PCP episodes that included
endoscopy, and 14.1% of GE episodes that included
endoscopy, also included esophageal ulcer diagnoses;
32.5% of PCP episodes and 33.3% of GE episodes that
included endoscopy also included esophagitis diagnoses;
3.2% of PCP episodes and 4.3% of GE episodes that
included endoscopy also included Barrett’s esophagus
diagnoses; and 10.0% of PCP episodes and 13.6% of GE
episodes that included endoscopy also included stricture
diagnoses. In addition, the analysis was reversed to com-
pare the rate of endoscopic procedure between ﬁrst PCP
and GE episodes that included each of the four conditions.
The results showed that: 75.8% of PCP episodes and 78.1%
of GE episodes that included esophageal ulcer diagnoses
also included endoscopy; 42.3% of PCP episodes and
78.6% of GE episodes that included esophagitis diagnoses
also included endoscopy; 72.7% of PCP episodes and
76.1% of GE episodes that included Barrett’s esophagus
diagnoses also included endoscopy; and 75.5% of PCP
episodes and 84.9% of GE episodes that included esopha-
geal stricture diagnoses also included endoscopy.
Table 4 provides the frequency of reasons for subject
transfer to GEs for GERD care. The most common reasons
for transfer of subjects to GEs were to address escalating or
an increasing number of symptoms, or evaluation of such
gastroenterologic symptoms as abdominal pain, heartburn,
chest pain, regurgitation, and indigestion (69 charts), fol-
lowed by endoscopy (51 charts), and insufﬁcient response
to GERD therapy (23 charts).
PPIs were, by far, the most prevalent GERD therapy
documented in both the PCP and GE charts, as documented
in Table 5. A change in GERD therapy regimen over time
was documented in 60% of the PCP charts. A change in
regimen typically meant changing the GERD medication
(N = 53 charts, 88.3% of charts with regimen change
documented), followed by a change in frequency of med-
ication administration (N = 10, 16.7%, data not shown).
Change in GERD therapy was documented in 42 GE
charts; again, the most prevalent change in therapy was a
change in the GERD medication (N = 10 charts, 23.8% of
charts with regimen change documented at ﬁrst visit),
followed by a change in frequency (N = 3, 7.1%, data not
shown). Reasons for therapy regimen change over time
were abstracted from both PCP and GE charts (Table 5).
The most common reasons for therapy regimen change
were a lack of improvement in GERD symptoms (51.7% of
PCP charts, 9.5% of GE charts) and insufﬁcient subject
response to therapy (51.7% of PCP charts, 26.2% of GE
charts). Nineteen percent of GE charts also documented
upper gastrointestinal (GI) endoscopy results as a reason
for therapy regimen change.
Eighty-seven (88%) of the GE charts showed that GEs
ordered at least one diagnostic endoscopy or esophagos-
copy (data not shown). Forty-six (46.5%) of the GE charts
explicitly documented that the GE transferred the subject
back to the PCP (data not shown); circumstances around
the return of subjects to the PCPs’ care included comple-
tion of endoscopic or other procedure (39 charts),
decreased symptom severity (4 charts), and improved
response to therapy (3 charts).
Discussion
This was a combined retrospective administrative claims
and medical chart review study that examined GERD-
related health care resource utilization, GERD therapy, and
reasons for transfer of subjects between PCPs and GEs.
The results of the descriptive claims-based analysis, med-
ical chart data analysis, and multivariate regression anal-
ysis were highly complementary and consistent.
Table 4 Reasons for transfers to GEs
Reason for referral from GE charts
a Number (%) of
charts
Endoscopic procedure 51 (51.5)
General gastroenterological symptoms (abdominal
or epigastric pain, bloating, gas, diarrhea,
indigestion, regurgitation, heartburn, chest pain)
34 (34.3)
Symptom severity 29 (29.3)
Patient not responding to GERD therapy 23 (23.2)
Existing or chronic GERD 19 (19.2)
Diagnostic procedure 14 (14.1)
Increasing number of symptoms 6 (6.1)
GE gastroenterologist
a Multiple reasons for referral could be selected; data from GE charts
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H2RA. PPIs were associated with signiﬁcantly lower like-
lihood of transfer both from PCP to GE and from GE to PCP
in the multivariate analysis, suggesting that PPI use is so
prevalent that it is unlikely to inﬂuence transfer decisions.
GE episodes, in general, were characterized by higher
rates of physician ofﬁce visits, endoscopic procedures,
esophageal repair and manipulation procedures, and addi-
tional GERD diagnostic procedures. Subjects who were
transferred to GEs were more likely to have endoscopies
than were subjects who were not transferred. Subjects
whose ﬁrst episodes were GE episodes tended to have
higher GERD severity levels and higher rates of baseline
comorbid conditions. Although the differences in the rates
of baseline comorbid conditions were statistically signiﬁ-
cant, they do not represent clinically signiﬁcant differences.
Subjects whose ﬁrst episodes were GE were more likely to
have general GI disorders, esophageal ulcer, esophagitis,
esophageal stricture, and Barrett’s esophagus. Moreover,
subjects with relatively severe GERD symptoms or com-
plications tended to be transferred to, or remain under the
care of, GEs; it is possible that the coefﬁcient for Barrett’s
esophagus in the PCP-to-GE transfer regression was not
signiﬁcant because a very small proportion of subjects in
ﬁrst PCP episodes had a diagnosis of Barrett’s esophagus.
Small proportions of subjects whose ﬁrst episodes were
PCP had diagnoses of Barrett’s esophagus or esophagitis or
esophageal stricture. We speculate that most of these
subjects were diagnosed with these conditions prior to our
study period, and were managed by PCPs. Moreover, it is
important to bear in mind how episodes were assigned to
PCP or GE, i.e., based on at least 55% of GERD-related
utilization. It is therefore possible that subjects with these
conditions who were under the care of PCPs could still
have been seen by GEs (and have even undergone endos-
copy) during their PCP episodes.
The additional analysis that compared the prevalence of
these conditions between PCP and GE episodes with
endoscopy mitigates the likelihood that the result that GEs
treat more severe GERD patients was biased by the higher
rate of endoscopic procedures among GEs.
Together, these results indicate that, in general, PCPs
treat GERD patients with mild symptoms and symptoms
that respond to initial GERD pharmaceutical therapy, while
patients whose symptoms do not respond to standard
GERD therapy, or whose symptoms are severe when they
begin care, are treated by GEs. These results also indicate
that PCPs empirically treat patients with GERD, usually
with a step-down approach, while GEs tend to adopt a more
resource-intensive treatment approach, including greater
numbers of ofﬁce visits and interventions.
There are limitations inherent to administrative claims,
which are collected for the purpose of payment and not for
research. A pharmacy claim for a ﬁlled prescription does
not indicate that the medication was consumed or that it
was taken as prescribed. OTC medications or those
Table 5 GERD therapy regimens documented in PCP and GE medical charts
PCP N = 100 charts GE N = 99 charts
a
N (%) N (%)
Documentation of antacid use 17 (17.0%) 7 (7.1%)
Documentation of PPI use 88 (88.0%) 84 (84.8%)
Documentation of H2RA use 26 (26.0%) 14 (14.1%)
Reasons for change in GERD therapy regimen over time
Any change in GERD therapy regimen over time 60 (60.0%) 42 (42.4%)
Symptoms did not change or worsened 31 (51.7%)
b 4 (9.5%)
c
Patient did not respond to therapy 31 (51.7%)
b 11 (26.2%)
c
Change in insurance coverage 4 (6.7%)
b 1 (2.4%)
c
Patient request 2 (3.3%)
b 0
Symptoms improved 0 3 (7.1%)
c
EGD results 0 8 (19.0%)
c
Other reason 6 (10.0%)
b 6 (14.3%)
c
No information in chart 9 (15.0%)
b 13 (31.0%)
c
PCPprimarycare physician,GE gastroenterologist, PPIprotonpumpinhibitor,H2RAH2-receptorantagonist, EGDesophagogastroduodenoscopy
a One GE chart had no information about the subject during the designated time period, thus data from 99 GE charts were analyzed
b Percentages are proportions of 60 PCP charts with documentation of change in GERD therapy regimen over time
c Percentages are proportions of 42 GE charts with documentation of change in GERD therapy regimen over time; multiple responses could be
selected
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the claims data; this qualiﬁcation might have led to an
underestimate of H2RA use within the study population. A
diagnosis code on a medical claim is not necessarily
positive presence of condition, as the diagnosis code may
have been coded incorrectly or included as a rule-out cri-
terion. For this study, however, subjects had to meet mul-
tiple clinical criteria, making inclusion based on rule-out
unlikely.
For this study speciﬁcally, there were additional limi-
tations. First, results are based primarily on subjects’
claims experience during the study period. Previous treat-
ment could not be observed, but likely contributed to the
rate of health care resource utilization during the ﬁrst and
subsequent treatment episodes. Furthermore, the absence of
clinical information in claims data does not allow us to
verify the inferences made with respect to physicians’
behavior and clinical motivations. Second, results from the
medical chart abstraction data should be applied to larger
populations cautiously; generalizability is limited. Third,
utilization of OTC medications for treatment of GERD
symptoms is an important component of care to understand
and quantify. It was, unfortunately, difﬁcult to know the
extent to which the rates of OTC antacid and H2RA use
reﬂected in the chart abstraction results are accurate or
generalizable among individuals with GERD. Fourth, the
criteria for assigning episodes to PCPs and GEs was made
purposefully, but may limit the generalizability of these
results; the alignment of the claims analysis results from
this study with those from survey analyses published in the
literature, as well as with those from the medical chart
abstraction, mitigates this limitation. Finally, integrating
information about ‘‘other’’ episodes was beyond the scope
of this study. Additional analysis suggested that other
episodes often included active participation by both PCPs
and GEs; thus, some information about PCP and GE
behaviors was excluded from this analysis.
This study provides a real-world examination of PCP
and GE treatment of GERD in a large, national population.
It provides important breadth to published physician-based
survey data on GERD treatment. The data showed that
PCPs tend to treat relatively uncomplicated cases of
GERD; their treatment approach appears to be empirical
and step-down, based on heavy PPI utilization. PCPs
transfer GERD patients to the care of GEs when the
patients do not respond to therapy and when their symp-
toms grow more severe. GEs tend to adopt a diagnostic
treatment approach with endoscopic procedures, and
transfer the care of the patient back to the PCP when
GERD symptoms are diagnosed with endoscopy or when
symptoms have improved. Based on these data, we spec-
ulate that timely transfers of patients with GERD symp-
toms from PCPs to GEs when empiric treatment appears to
be insufﬁcient may lead to more effective and efﬁcient
management of GERD.
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